[Worldwide, cervical cancer remains the second most frequent malignancy. The estimated number of new cases is 450,000 per year. Approximately 80% of affected women live in developing countries where access to cervical screening programmes is limited. In Europe, more than 12,800 women die each year from this preventable disease. Human papilloma virus (HPV) infection has been proved to be a potential cause of cervical cancer. Secondary screening decreases the morbidity and mortality of the disease, but does not prevent HPV infection. HPV-DNA can be detected in 90-100% of preinvasive and invasive cervical cancer cases. Trials assessing prophylactic anti-HPV vaccination have confirmed that the vaccination is a suitable method for the primary prevention of precancer lesions and cervical cancer.]
COMMENTS
0 comments